Filtered By:
Cancer: Colorectal Cancer
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 59897 results found since Jan 2013.
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer
Annu Rev Med. 2021 Jan 27;72:399-413. doi: 10.1146/annurev-med-070119-120448.ABSTRACTPatient-specific biomarkers form the foundation of precision medicine strategies. To realize the promise of precision medicine in patients with colorectal cancer (CRC), access to cost-effective, convenient, and safe assays is critical. Improvements in diagnostic technology have enabled ultrasensitive and specific assays to identify cell-free DNA (cfDNA) from a routine blood draw. Clinicians are already employing these minimally invasive assays to identify drivers of therapeutic resistance and measure genomic heterogeneity, particularly whe...
Source: Annual Review of Medicine - January 27, 2021 Category: General Medicine Authors: Van K Morris John H Strickler Source Type: research
Gut Microbiota in Tumor Microenvironment: A Critical Regulator in Cancer Initiation and Development as Potential Targets for Chinese Medicine
Am J Chin Med. 2021 Mar 4:1-18. doi: 10.1142/S0192415X21500270. Online ahead of print.ABSTRACTCancer is a disease with a high mortality and disability rate. Cancer consists not only of cancer cells, but also of the surrounding microenvironment and tumor microenvironment (TME) constantly interacting with tumor cells to support tumor development and progression. Over the last decade, accumulating evidence has implicated that microbiota profoundly influences cancer initiation and progression. Most research focuses on gut microbiota, for the gut harbors the largest collection of microorganisms. Gut microbiota includes bacteria...
Source: The American Journal of Chinese Medicine - March 8, 2021 Category: Complementary Medicine Authors: Li Wang Fu Peng Cheng Peng Jun-Rong Du Source Type: research
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer
Annu Rev Med. 2021 Jan 27;72:399-413. doi: 10.1146/annurev-med-070119-120448.ABSTRACTPatient-specific biomarkers form the foundation of precision medicine strategies. To realize the promise of precision medicine in patients with colorectal cancer (CRC), access to cost-effective, convenient, and safe assays is critical. Improvements in diagnostic technology have enabled ultrasensitive and specific assays to identify cell-free DNA (cfDNA) from a routine blood draw. Clinicians are already employing these minimally invasive assays to identify drivers of therapeutic resistance and measure genomic heterogeneity, particularly whe...
Source: Annual Review of Medicine - January 27, 2021 Category: General Medicine Authors: Van K Morris John H Strickler Source Type: research
Gut Microbiota in Tumor Microenvironment: A Critical Regulator in Cancer Initiation and Development as Potential Targets for Chinese Medicine
Am J Chin Med. 2021 Mar 4:1-18. doi: 10.1142/S0192415X21500270. Online ahead of print.ABSTRACTCancer is a disease with a high mortality and disability rate. Cancer consists not only of cancer cells, but also of the surrounding microenvironment and tumor microenvironment (TME) constantly interacting with tumor cells to support tumor development and progression. Over the last decade, accumulating evidence has implicated that microbiota profoundly influences cancer initiation and progression. Most research focuses on gut microbiota, for the gut harbors the largest collection of microorganisms. Gut microbiota includes bacteria...
Source: The American Journal of Chinese Medicine - March 8, 2021 Category: Complementary Medicine Authors: Li Wang Fu Peng Cheng Peng Jun-Rong Du Source Type: research
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer
Annu Rev Med. 2021 Jan 27;72:399-413. doi: 10.1146/annurev-med-070119-120448.ABSTRACTPatient-specific biomarkers form the foundation of precision medicine strategies. To realize the promise of precision medicine in patients with colorectal cancer (CRC), access to cost-effective, convenient, and safe assays is critical. Improvements in diagnostic technology have enabled ultrasensitive and specific assays to identify cell-free DNA (cfDNA) from a routine blood draw. Clinicians are already employing these minimally invasive assays to identify drivers of therapeutic resistance and measure genomic heterogeneity, particularly whe...
Source: Annual Review of Medicine - January 27, 2021 Category: General Medicine Authors: Van K Morris John H Strickler Source Type: research
Gut Microbiota in Tumor Microenvironment: A Critical Regulator in Cancer Initiation and Development as Potential Targets for Chinese Medicine
Am J Chin Med. 2021 Mar 4:1-18. doi: 10.1142/S0192415X21500270. Online ahead of print.ABSTRACTCancer is a disease with a high mortality and disability rate. Cancer consists not only of cancer cells, but also of the surrounding microenvironment and tumor microenvironment (TME) constantly interacting with tumor cells to support tumor development and progression. Over the last decade, accumulating evidence has implicated that microbiota profoundly influences cancer initiation and progression. Most research focuses on gut microbiota, for the gut harbors the largest collection of microorganisms. Gut microbiota includes bacteria...
Source: The American Journal of Chinese Medicine - March 8, 2021 Category: Complementary Medicine Authors: Li Wang Fu Peng Cheng Peng Jun-Rong Du Source Type: research
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer
Annu Rev Med. 2021 Jan 27;72:399-413. doi: 10.1146/annurev-med-070119-120448.ABSTRACTPatient-specific biomarkers form the foundation of precision medicine strategies. To realize the promise of precision medicine in patients with colorectal cancer (CRC), access to cost-effective, convenient, and safe assays is critical. Improvements in diagnostic technology have enabled ultrasensitive and specific assays to identify cell-free DNA (cfDNA) from a routine blood draw. Clinicians are already employing these minimally invasive assays to identify drivers of therapeutic resistance and measure genomic heterogeneity, particularly whe...
Source: Annual Review of Medicine - January 27, 2021 Category: General Medicine Authors: Van K Morris John H Strickler Source Type: research
